Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive fatal disorder that affects all skeletal muscles, leading to death, mostly within 2-4 years from onset. To date, the anti-glutamatergic drug riluzole is the only drug that has been approved for the treatment of this disease; however, its efficacy is modest. Oxidative stress is considered to be involved in the pathology of ALS, and in this regard, the free radical scavenger edaravone, which was originally developed for the treatment of acute ischemic stroke, has also been developed for the treatment of ALS. Areas covered: This review describes the pharmacological properties of edaravone and the progress of clinical trials conducted to evaluate the efficacy of this drug in the treatment of ALS. Expert commentary: Edaravone is the first drug to show effective inhibition of the motor function deterioration experienced by ALS patients with early-stage probable and definite types. In order to effectively prolong the quality of motor function, edaravone treatment should be initiated as soon as the diagnosis has been confirmed; however, the respiratory function should be carefully monitored when a deterioration in breathing capacity is detected.
References
Oct 24, 1997·Annals of Neurology·M F BealR H Brown
Jul 13, 1999·Annals of Neurology·H TohgiC Isobe
Apr 29, 2003·Cerebrovascular Diseases·UNKNOWN Edaravone Acute Infarction Study Group
Jun 19, 2004·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·P Nigel LeighLeonard Van Den Berg
Jan 12, 2005·Neurology·P KaufmannH Mitsumoto
Nov 28, 2006·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Hiide Yoshino, Akio Kimura
Dec 6, 2008·Clinical and Experimental Nephrology·Akira Hishida
May 1, 2012·Journal of Neurology, Neurosurgery, and Psychiatry·Tadashi KanouchiTakanori Yokota
Oct 7, 2014·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Koji AbeUNKNOWN Edaravone ALS Study Group
Oct 16, 2014·Lancet Neurology·Hiroshi MitsumotoVincenzo Silani
Jan 5, 2016·Revue neurologique·P CouratierB Marin
Oct 1, 1996·Redox Report : Communications in Free Radical Research·Y YamamotoK Watanabe
May 20, 2017·Lancet Neurology·UNKNOWN Writing Group, UNKNOWN Edaravone (MCI-186) ALS 19 Study Group
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Yoshinobu NakamaruMasayuki Suzuki
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Koji TakeiJoseph Palumbo
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·UNKNOWN WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·UNKNOWN EDARAVONE (MCI-186) ALS 16 STUDY GROUP
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·UNKNOWN WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Alexander KalinMasahiko Wasaki
Jan 6, 2018·Orphanet Journal of Rare Diseases·Marc Dooms, Maria Carvalho
Mar 7, 2018·Orphanet Journal of Rare Diseases·Thomas Hilberg
Jul 27, 2018·Current Opinion in Neurology·Jason R ThonhoffStanley H Appel
Dec 6, 2018·Orphanet Journal of Rare Diseases·Yanfei ZhuMin Zhu
Oct 28, 2019·Rinshō shinkeigaku = Clinical neurology·Tsuyoshi Matsumura, Hirofumi Komaki
Citations
May 31, 2019·International Journal of Molecular Sciences·Natalia NowickaJoanna Wojtkiewicz
Jun 17, 2020·Clinical Pharmacology in Drug Development·Hidetoshi ShimizuKazuoki Kondo
May 22, 2020·Acta neurologica Belgica·C QuarracinoG E Rodríguez
Oct 23, 2020·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Zaynab ShakkourFiras Kobeissy
Nov 26, 2020·Cellular and Molecular Neurobiology·Zhenzhen XuRenshi Xu
Sep 18, 2020·Immunology·Falguni BaidyaPallab Bhattacharya
Dec 18, 2020·Frontiers in Cellular Neuroscience·Luke McAlaryNeil R Cashman
Mar 30, 2021·Yonsei Medical Journal·Jang Woo LeeWon Ah Choi
May 27, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Qinqin ZhaoXiang Li
Jun 18, 2021·Cell Death & Disease·Nunzio VicarioRosario Gulino
Aug 29, 2021·Pharmaceuticals·Hideki HouzenIchiro Yabe
Oct 3, 2021·Neurotoxicity Research·Sally KellinyXin-Fu Zhou
Oct 5, 2021·EMBO Molecular Medicine·Antonietta TaralloGiancarlo Parenti
Jan 11, 2022·JAMA Neurology·Simon WitzelUNKNOWN German Motor Neuron Disease Network (MND-NET)